Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Impact Therapeutics (Shanghai), Inc. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters span 6 distinct examiners and 6 distinct art units, showing a fully distributed examination profile across the active portfolio.
HABTE, KAHSAY is the busiest examiner, with 1 pending action. Portfolio management should emphasize separate response calendars and matter-specific analysis rather than relying on a shared examiner or art-unit strategy.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HABTE, KAHSAY | 1 | 84.9% | +7.5% |
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +39.1% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| ISMAIL, REHANA | 1 | 76.2% | +34.8% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.3% | +43.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18702540 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | HABTE, KAHSAY | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552434 | ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF | BASQUILL, SEAN M | 5d overdue |
| 18006603 | COMBINATION THERAPY OF PARP INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 42d |
| 18554980 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552434 | ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF | BASQUILL, SEAN M | 5d overdue |
| 18259112 | SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF | ISMAIL, REHANA | 7d |
| 18006603 | COMBINATION THERAPY OF PARP INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 42d |
| 18554980 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1699 | 1 |
| 1622 | 1 |
| 1614 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18702540 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18687111 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | OTTON, ALICIA L | 1699 | §102§112DP | Final Rejection | — | Pending | Feb 27, 2024 |
| 18554980 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §102§112 | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18552434 | ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF | BASQUILL, SEAN M | 1614 | §103§112 | Final Rejection | 5d overdue | Pending | Sep 25, 2023 |
| 18259112 | SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF | ISMAIL, REHANA | 1625 | §112 | Non-Final OA | 7d | Pending | Jun 23, 2023 |
| 18006603 | COMBINATION THERAPY OF PARP INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103§112 | Non-Final OA | 42d | Pending | Jan 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImpact Therapeutics (Shanghai), Inc. has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Kahsay Habte has the most, with 1 of Impact Therapeutics (Shanghai), Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
